简体
简体中文
繁體中文

哈勃集团 HUBB

等待开盘 07-25 09:30:00 美东时间

437.50

+2.550

+0.59%

华盛通华盛通
立即下载
  • 最 高438.95
  • 今 开435.00
  • 成交量 60.15万股
  • 最 低 433.29
  • 昨 收 434.95
  • 总市值 233.51亿
  • 52周最高 477.385
  • 市盈率 30.43
  • 换手率 0.00%
  • 52周最低 298.105
  • 委 比 -63.64%
  • 总股本 5337.26万
  • 历史最高 477.385
  • 量 比 1.08
  • 振 幅 1.30%
  • 历史最低 6.03
  • 每 手 1
  • 风险率 38.57%

个股概要

财务分析

公司资料

相关新闻

分红派息

  • 分时图
  • 日k
  • 周k
  • 月k

相关新闻

更多
  • Hubbell to Announce Second Quarter 2025 Results on July 29, 2025

    <p>Hubbell Incorporated will release its second quarter 2025 financial results before the market opens on July 29, 2025. The company will host an Analysts' Conference Call at 10:00 AM ET to discuss the results. The press release and conference call materials will be available on Hubbell's website under the "Press Releases" and "Events/Presentations" sections. Hubbell, a leading manufacturer of utility and electrical solutions, reported 2024 reven...

    07-10 20:40

  • Barclays Maintains Equal-Weight on Hubbell, Raises Price Target to $420

    Barclays analyst Julian Mitchell maintains Hubbell (NYSE:HUBB) with a Equal-Weight and raises the price target from $414 to $420.

    07-09 23:35

  • 美股大行评级 | 潜在涨幅83.3%!Robinhood获Keybanc升目标价至110美元,维持"超配"评级

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1147088025548091392.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Leerink Partners:维持再鼎医药(ZLAB)"跑赢大市"评级,目标价从73美元升至75美元</p> <p>• 美银证券:维持BioCryst Pharma(BCRX)"买入"评级,目标价从13美元升至15美元

    07-02 09:54

  • Wells Fargo Maintains Equal-Weight on Hubbell, Raises Price Target to $420

    Wells Fargo analyst Joseph O&#39;Dea maintains Hubbell (NYSE:HUBB) with a Equal-Weight and raises the price target from $363 to $420.

    07-01 21:55

  • 美股大行评级 | 潜在涨幅434.95%!VNRX获Jones Trading首予"买入"评级,目标价3美元

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim:维持Metsera(MTSR)"买入"评级,目标价从56美元升至62美元</p> <p>• 摩根大通:维持Avidity Biosciences(RNA)"超配"评级,目标价从57美元升至59美元</

    06-11 09:43

  • 美股大行评级 | eToro Group获多家大行首予买入评级,甲骨文获多家机构上调目标价

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139116149842006017.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright &amp; Co.:维持PolyPid(PYPD)"买入"评级,目标价从11美元升至13美元</p> <p>• HC Wainwright &amp; Co.:维持Vertical Aerosp

    06-10 09:45

  • What 4 Analyst Ratings Have To Say About Hubbell

    Throughout the last three months, 4 analysts have evaluated Hubbell (NYSE:HUBB)...

    06-10 05:00

  • Barclays Maintains Equal-Weight on Hubbell, Raises Price Target to $414

    Barclays analyst Julian Mitchell maintains Hubbell (NYSE:HUBB) with a Equal-Weight and raises the price target from $400 to $414.

    06-10 00:58

  • 美股大行评级 | 潜在涨幅2840.31%!Mersana Therapeutics获Truist Securities升目标价至10美元,维持"买入"评级

    <span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1130419824951111681.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Truist Securities:维持Mersana Therapeutics(MRSN)"买入"评级,目标价从9美元升至10美元</p> <p>• Guggenheim:维持Cabaletta Bio(CABA)"买入

    05-17 08:44

  • JP Morgan Maintains Neutral on Hubbell, Raises Price Target to $417

    JP Morgan analyst Stephen Tusa maintains Hubbell (NYSE:HUBB) with a Neutral and raises the price target from $352 to $417.

    05-17 04:45